Home » Stocks » SIOX

Sio Gene Therapies, Inc. (SIOX)

Stock Price: $2.14 USD 0.07 (3.38%)
Updated May 14, 2021 4:00 PM EDT - Market closed
After-hours: $2.07 -0.07 (-3.27%) May 14, 7:59 PM
Market Cap 125.73M
Revenue (ttm) n/a
Net Income (ttm) -45.74M
Shares Out 58.75M
EPS (ttm) -1.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $2.14
Previous Close $2.07
Change ($) 0.07
Change (%) 3.38%
Day's Open 2.09
Day's Range 2.05 - 2.17
Day's Volume 904,387
52-Week Range 1.86 - 5.74

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts appe...

Other stocks mentioned: AGEN, ATOS, CDMO, COCP, OCGN, SIGA
4 days ago - InvestorPlace

NEW YORK, and RESEARCH TRIANGLE PARK, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transfor...

2 weeks ago - GlobeNewsWire

NEW YORK and RESEARCH TRIANGLE PARK, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve t...

1 month ago - GlobeNewsWire

NEW YORK and RESEARCH TRIANGLE PARK, N.C., March 15, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform...

2 months ago - GlobeNewsWire

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve th...

3 months ago - GlobeNewsWire

Sio Gene Therapies Inc (NASDAQ: SIOX) has received $11.6 million from closing the sale of Arvelle Therapeutics to Angelini Pharma.

3 months ago - Benzinga

Sio Gene Therapies Inc (NASDAQ: SIOX) has dosed the first patient in Phase 1/2 trial evaluating AXO-AAV-GM2 investigational gene therapy to treat GM2 gangliosidosis, also known as Tay-Sachs or Sandhoff ...

3 months ago - Benzinga

- First potentially disease-modifying gene therapy for GM2 gangliosidosis to enter clinical studies - Expect to continue patient identification, screening, and enrollment in Stage 1 of the study through...

3 months ago - GlobeNewsWire

-  Generally well-tolerated with a favorable safety profile in five patients -  Serum beta-galactosidase enzyme activity increased in all patients at all timepoints between Day 7 and Month 6, representi...

5 months ago - GlobeNewsWire

Axovant (SIOX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Other stocks mentioned: AXGT
5 months ago - Zacks Investment Research

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform ...

Other stocks mentioned: AXGT
5 months ago - GlobeNewsWire

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform...

Other stocks mentioned: AXGT
5 months ago - GlobeNewsWire

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform...

Other stocks mentioned: AXGT
6 months ago - GlobeNewsWire

NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for neurodegenerative diseases, today a...

Other stocks mentioned: AXGT
6 months ago - GlobeNewsWire

NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Drug Adminis...

Other stocks mentioned: AXGT
6 months ago - GlobeNewsWire

NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that it will host a virtual R&D Day...

Other stocks mentioned: AXGT
6 months ago - GlobeNewsWire

NEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it h...

Other stocks mentioned: AXGT
7 months ago - GlobeNewsWire

The FDA bestows a Rare Pediatric Disease status on Axovant's (AXGT) gene therapy candidate AXO-AAV-GM1, which is being developed for the treatment of GM1 gangliosidosis. Stock appreciates.

Other stocks mentioned: AXGT
7 months ago - Zacks Investment Research

Company on-track to report data from ongoing Phase 1/2 clinical study in Q4 2020 Company on-track to report data from ongoing Phase 1/2 clinical study in Q4 2020

Other stocks mentioned: AXGT
7 months ago - GlobeNewsWire

Investors need to pay close attention to Axovant (AXGT) stock based on the movements in the options market lately.

Other stocks mentioned: AXGT
7 months ago - Zacks Investment Research

NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced the appoi...

Other stocks mentioned: AXGT
7 months ago - GlobeNewsWire

• AXO-Lenti-PD was well-tolerated with no treatment - related serious adverse events at 6 months • 2 1- point mean improvement i n UPDRS Part III “OFF” score, a 40 % improvement from baseline , exceedin...

Other stocks mentioned: AXGT
7 months ago - GlobeNewsWire

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the Company will present at up...

Other stocks mentioned: AXGT
7 months ago - GlobeNewsWire

These underappreciated biotechnology start-ups could turn heads one day -- but not yet.

Other stocks mentioned: AXGT, BBIO
7 months ago - The Motley Fool

AXGT has promising gene therapy results in Parkinson's Disease.

Other stocks mentioned: AXGT
7 months ago - Seeking Alpha

Axovant (AXGT) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.

Other stocks mentioned: AXGT
7 months ago - Zacks Investment Research

Week 39 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

Other stocks mentioned: AAPL, AXGT, AXP, JPM, KO, MCD, MRK ...
7 months ago - Seeking Alpha

NEW YORK and BASEL, Switzerland, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, ...

Other stocks mentioned: AXGT
8 months ago - GlobeNewsWire

      - Parkinson's Disease R&D Day to be hosted by Gavin Corcoran, MD, Chief R&D Officer, on October 30th, 2020, with leading movement disorder specialists

Other stocks mentioned: AXGT
8 months ago - GlobeNewsWire

NEW YORK and BASEL, Switzerland, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene therapy company developing innovative gene therapies for neurodegener...

Other stocks mentioned: AXGT
9 months ago - GlobeNewsWire

Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant Gene Therapies for Manufacture and Supply of AXO-Lenti-PD           

Other stocks mentioned: AXGT
9 months ago - GlobeNewsWire

NEW YORK and BASEL, Switzerland, July 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, a...

Other stocks mentioned: AXGT
9 months ago - GlobeNewsWire

Axovant Gene Therapies (AXGT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Other stocks mentioned: AXGT
10 months ago - Zacks Investment Research

NEW YORK and BASEL, Switzerland, June 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, t...

Other stocks mentioned: AXGT
11 months ago - GlobeNewsWire

-  Six-month data from low-dose cohort expected in Q4 2020 -  IND amended to include Type I (infantile onset) patients and to evaluate a higher dose -  Expect to initiate high-dose cohort in 2H 2020

Other stocks mentioned: AXGT
11 months ago - GlobeNewsWire

Axovant (AXGT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Other stocks mentioned: AXGT
11 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for May 5th

Other stocks mentioned: AXGT, GFI, PS, ZYXI
1 year ago - Zacks Investment Research

Company’s balance sheet is now free of debt Company’s balance sheet is now free of debt

Other stocks mentioned: AXGT
1 year ago - GlobeNewsWire

NEW YORK and BASEL, Switzerland, April 15, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies for neurological diseases, today announce...

Other stocks mentioned: AXGT
1 year ago - GlobeNewsWire

Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Other stocks mentioned: AXGT
1 year ago - Zacks Investment Research

NEW YORK and BASEL, Switzerland, April 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases,...

Other stocks mentioned: AXGT
1 year ago - GlobeNewsWire

NEW YORK and BASEL, Switzerland, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the closing of its previously announced underwritten public of...

Other stocks mentioned: AXGT
1 year ago - GlobeNewsWire

NEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the pricing of its underwritten public offering of 14,031,336 ...

Other stocks mentioned: AXGT
1 year ago - GlobeNewsWire

NEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced that it has commenced an underwritten public offering of its c...

Other stocks mentioned: AXGT
1 year ago - GlobeNewsWire

NEW YORK and BASEL, Switzerland, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today provided financial r...

Other stocks mentioned: AXGT
1 year ago - GlobeNewsWire

NEW YORK and BASEL, Switzerland, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, ...

Other stocks mentioned: AXGT
1 year ago - GlobeNewsWire

Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Other stocks mentioned: AXGT
1 year ago - Zacks Investment Research

NEW YORK and BASEL, Switzerland, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT) today announced preliminary findings from an expanded access treatment in which a single p...

Other stocks mentioned: AXGT
1 year ago - GlobeNewsWire

The FDA grants Orphan Drug status to Axovant's (AXGT) gene therapy candidate, AXO-AAV-GM1, being developed for the treatment of GM1 gangliosidosis. Shares decline despite the positive news.

Other stocks mentioned: AXGT
1 year ago - Zacks Investment Research

NEW YORK and BASEL, Switzerland, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U...

Other stocks mentioned: AXGT
1 year ago - GlobeNewsWire

About SIOX

Sio Gene Therapies, Inc., a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School. The company was formerly known as Axovant Gen... [Read more...]

Industry
Biotechnology
Founded
2014
CEO
Pavan Cheruvu
Employees
38
Stock Exchange
NASDAQ
Ticker Symbol
SIOX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SIOX stock is "Buy." The 12-month stock price forecast is 8.70, which is an increase of 306.54% from the latest price.

Price Target
$8.70
(306.54% upside)
Analyst Consensus: Buy